Company: TVRD
Filing Date: 2025-10-07
Form Type: S-1/A
Source: 0001104659-25-097519
Chunk: 234

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-07
Form: S-1/A
Chunk 234
---
 based on such evaluation; |

| ● | reviewing and approving, or recommending to the full Board, individual and corporate performance goals and objectives of the Company’s other executive officers and reviewing and approving, or recommending to the full Board, their compensation; |

| ● | reviewing and approving of the compensation and other terms of employment or service, including severance and change-in-control arrangements and any post-employment agreements, applicable to the Company’s executive officers; |

| ● | reviewing and recommending to the Board the compensation of directors; |

| ● | administering of the Company’s equity compensation plans, 401(k) plan, and other similar plans and programs; |

| ● | preparing a compensation committee report on executive compensation as may be required from time to time to be included in the Company’s annual proxy statements or annual reports on Form 10-K filed with the SEC; |

| ● | reviewing and discussing with management the Company’s Compensation Discussion and Analysis that the Company may be required from time to time to include in proxy statements and other SEC filings and considering whether to recommend that it be included in such filings; |

| ● | providing recommendations to the full Board on compensation-related proposals to be considered at our annual meeting of the stockholders and reviewing and considering the results of any advisory vote on executive compensation; |

| ● | reviewing and making recommendations to the Board related to management succession; |

| ● | establishing, approving, modifying and overseeing our compensation clawback or similar policies and any required recoupment disclosures; and |

137

| ● | overseeing risk management of our compensation policies and practices on at least an annual basis and considering whether risk arising from our compensation policies and practices are reasonably likely to have a material adverse risk on the Company. |

The members of the compensation committee are Sujal Shah, Wallace Hall and Susan Shiff. Sujal Shah is the chair of the compensation committee. Each member of our compensation committee is a “non-employee” director within the meaning of Rule 16b-3 of the rules promulgated under the Exchange Act and independent within the meaning of the independent director guidelines of Nasdaq. The composition of the compensation committee complies with the applicable requirements of the rules and regulations of Nasdaq. Nominating and Corporate Governance Committee The nominating and corporate governance committee is responsible for overseeing our corporate governance functions on behalf of the Board, including:

| ● | identifying, reviewing, and evaluating candidates to serve on the Board consistent with criteria approved by the Board, including consideration of the potential conflicts of interest and